Core Viewpoint - Meicheng Technology faces administrative penalties due to false financial reporting, with a cumulative inflated revenue of 1.438 billion yuan and inflated profits of 658 million yuan from 2014 to 2018 [3][8][9]. Financial Misreporting - The company reported inflated revenues of 23.66 million yuan, 373 million yuan, 726 million yuan, 215 million yuan, and 101 million yuan for the years 2014 to 2018, respectively, accounting for 2.06%, 20.67%, 24.60%, 5.53%, and 2.88% of the disclosed revenue for those years [8]. - The inflated profits for the same years were 22.93 million yuan, 189 million yuan, 260 million yuan, 117 million yuan, and 69.49 million yuan, representing 17.91%, 75.64%, 49.78%, 15.49%, and 15.58% of the disclosed profit totals [8]. Regulatory Actions - The Shandong Securities Regulatory Bureau has proposed a fine of 600,000 yuan for the company and a total of 2.3 million yuan for 12 responsible individuals, including a 10-year market ban for Guo Baifeng, the former chairman of the subsidiary involved in the fraud [9][10]. - Starting September 30, the company's stock will be marked with a risk warning and will change its name to ST Meicheng, while the stock code remains the same [10][11]. Financial Performance - Meicheng Technology has reported continuous losses for four consecutive years from 2021 to 2024, with a total loss amounting to 3.683 billion yuan [12][13]. - The company attributes its ongoing losses primarily to declining performance in its landscaping business and difficulties in project payment collections [16]. Asset Disposal Strategy - To mitigate losses, Meicheng Technology is in the process of selling off its loss-making assets, particularly those related to the landscaping business [17]. - The company plans to divest 100% of its stake in the subsidiary, Saisiyuanlin, and has already initiated the transfer of several related companies [17]. Market Position - As of September 26, Meicheng Technology's stock closed at 3.22 yuan per share, with a market capitalization of 4.643 billion yuan [18].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 ● 风险提示 本次交易尚处于筹划阶段，交易各方就交易事项仍在商讨，目前就交易核心条款还存在较大分歧，本次 交易存在不确定性。 截至本公告披露之日，公司及相关方正商讨论证本次交易的可行性，就交易核心条款还存在较大分歧， 本次交易存在不确定性。公司将继续按照《上市公司重大资产重组管理办法》及其他相关规定，及时履 行信息披露义务。 三、风险提示 本次交易尚处于筹划阶段，交易各方就交易事项仍在商讨，目前就交易核心条款还存在较大分歧，本次 交易存在不确定性。 本次交易需按照相关法律、法规及公司章程的规定履行必要的决策和审批程序，最终能否实施存在不确 定性。 公司指定信息披露媒体为《上海证券报》、《中国证券报》、《证券时报》、《证券日报》及上海证券 交易所网站（www.sse.com.cn），有关公司的信息均以在上述指定信息披露媒体刊登的公告信息为准。 公司将根据相关事项的进展情况及时履行信息披露义务。 敬请广大投资者理性投资，注意投资风 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、重大资产重组事项概述 登录新浪财经APP 搜索【信披】查看更多考评等级 2024年12月31日，公司召开十一届二十四次临时董事会会议、十一届十一次临时监事会会议，审议通过 了《关于〈天津津投城市开发股份有限公司重大资产置换、发行股份及支付现金购买资产并募集配套资 金暨关联交易预案〉及其摘要的议案》等与本次交易相关的议案，具体内容详见公司披露的《天津津投 城市开发股份有限公司重大资产置换、发行股份及支付现金购买资产并募集配套资金暨关联交易预案》 及相关公告。 2025年1月25日，公司披露了《关于重大资产重组的进展公告》（公告编号：2025-014）。2025年2月25 日，公司披露了《关于重大资产重组的进展公告》（公告编号：2025-023）。2025年3月25日，公司披 露了《关于重大资产重组的进展公告》（公告编号：2025-030）。2025年4月25日，公司披露了《关于 重大资产重组的进展公告》（公告编号：2025-035）。2025年5月23日，公司披露了《关于重大资 ...

图片来源：富煌钢构公告 《每日经济新闻》记者（以下简称每经记者）注意到，此前富煌钢构股价出现大幅上涨，而后其发布了重大资产重组计划，拟收购大股东旗下的视觉科技公 司——合肥中科君达视界技术股份有限公司（以下简称"中科视界"）。 登录新浪财经APP 搜索【信披】查看更多考评等级 每经记者｜赵李南 每经编辑｜魏文艺 9月26日，富煌钢构（SZ002743，股价5.91元，市值25.72亿元）公告称，公司于当日收到中国证监会的《立案告知书》。因涉嫌信息披露违法违规，证监会 决定对公司立案。 目前，尚不能确认中国证监会此次立案与富煌钢构股价"抢跑"重大资产重组公告有关。 股价"抢跑"引质疑，公司曾否认筹划重组 时间回到2024年10月，富煌钢构的股价开始出现异常波动，连续收获多个涨停板。 从2024年10月24日至12月5日，富煌钢构区间涨幅高达75.11%。股价的异动引起了投资者的关注。 在投资者互动平台上，有投资者提问，公司实控人旗下如中科视界等优质资产是否会注入上市公司。对此，据媒体报道，富煌钢构明确回复称，"公司目前 暂无并购重组计划"。 然而，就在公司公开否认重组计划后不到一个月，2024年12月5日晚间， ...

Core Viewpoint - Dongxing Medical (301290) announced on September 26 that it plans to acquire 90% of Wuhan Yijiaobao Biological Materials Co., Ltd. through cash payment, which, if successful, will make Wuhan Yijiaobao a subsidiary of Dongxing Medical. This transaction is expected to constitute a major asset restructuring [1][6]. Group 1: Acquisition Details - The acquisition involves signing a "Share Purchase Intent Agreement" with all shareholders of Wuhan Yijiaobao, a high-tech enterprise focused on the R&D, production, and sales of high-end orthopedic and biomedical materials [5][6]. - The transaction is still in the preliminary planning stage, requiring further verification and negotiation of the transaction terms. Both the listed company and the target company must complete necessary internal and external decision-making and approval processes [6]. Group 2: Company Background - Dongxing Medical is a leading enterprise in the field of laparoscopic staplers, with a market capitalization of 2.801 billion yuan as of September 26, closing at 27.96 yuan per share [4]. - The company primarily engages in the R&D, production, and sales of surgical medical devices, including laparoscopic staplers and surgical equipment [7]. Group 3: Financial Performance - In the first half of 2025, Dongxing Medical reported revenue of approximately 183 million yuan, a year-on-year decrease of 14.17%, and a net profit attributable to shareholders of approximately 30.29 million yuan, down 36.47% year-on-year [7]. - The company announced the termination of its initial public offering fundraising project related to "Zihang Medical Device Components Intelligent Manufacturing and Expansion Project" and postponed the project "Weike Medical Minimally Invasive Surgical New Product Project" to December 31, 2027 [7].

以下文章来源于e公司 ，作者证券时报 吴志 e公司 . e公司，证券时报旗下专注上市公司新媒体产品，立志打造A股上市公司资讯第一平台。提供7x24小时上市公司标准化快讯，针对可能影响上市公司股价的 主题概念、行业事件及时采访二次解读，从投资者需求出发，直播上市公司有价值的活动、会议。 东星医疗拟收购武汉医佳宝90%股权。 9月26日，东星医疗（301290）公告，拟以支付现金方式购买武汉医佳宝生物材料有限公司（以下简称"武汉医佳宝"或"标的公司"）90%的股权。此次交易如能 顺利实施，武汉医佳宝将成为东星医疗的控股子公司。 根据公告，此次收购基于公司业务发展战略的需要。 具体来看，东星医疗拟以支付现金的方式，收购武汉医佳宝90%的股权。若本次交易能顺利实施完成，公司将持有武汉医佳宝90%的股权。 目前，此次交易尚处于初步筹划阶段。2025年9月26日，东星医疗已经与武汉医佳宝全体股东签订了《股权收购意向协议》，但最终收购股权比例、交易对方 及交易价格尚需交易各方进一步协商后确定。 东星医疗表示，根据初步研究和测算，本次交易预计构成《上市公司重大资产重组管理办法》规定的重大资产重组。本次交易不会导致上市公司控股 ...

9月26日，*ST宇顺再度涨停，股价来到41.31元/股，总市值115.77亿元，同时年内涨幅则达到了1060.39%。 | *ST宇顺(002289) | | --- | 今日（9月26日），*ST宇顺逆市涨停，股价报收于41.31元/股，总市值115.77亿元。 值得注意的是，年初至今，其股价涨幅已经超过 1000%，在全A股中，仅次于上纬新材（年内涨幅1891.59%）。整个ST板块，则已有9股年内涨幅超100%。 *ST宇顺股价年内涨超10倍 资料显示，*ST宇顺成立于2004年，2009年登陆深交所，主营业务为液晶显示屏及模组、触摸屏及模组、触摸显示一体化模组等产品的研 发、生产和销售。主要产品包括各类手机、平板、小家电显示屏。 公司股价今年大幅上涨或与公司筹划重大资产重组加码智算赛道有关。根据公司披露的并购重组公告，公司拟向交易对方凯星有限公司、正 嘉有限公司、上海汇之顶管理咨询有限公司支付现金购买其持有的中恩云（北京）数据科技有限公司、北京申惠碧源云计算科技有限公司、 中恩云（北京）数据信息技术有限公司100%的股权，本次收购构成《上市公司重大资产重组管理办法》规定的重大资产重组，但不构成关 联 ...

Core Viewpoint - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao, which is expected to constitute a major asset restructuring [2][7]. Group 1: Acquisition Details - On September 26, Dongxing Medical signed a "Share Acquisition Intent Agreement" with all shareholders of Wuhan Yijiaobao to purchase 90% of its equity for cash [7]. - The final transaction price will be based on an evaluation report from a qualified asset appraisal agency as per the Securities Law of the People's Republic of China [11]. - A exclusivity period is established from the signing of the agreement until May 31, 2026, during which the current shareholders cannot negotiate with other parties regarding the equity transfer [12]. Group 2: Strategic Rationale - The acquisition aligns with Dongxing Medical's business development strategy and aims to integrate high-quality industry resources, extending its surgical medical device supply chain and actively expanding into the synthetic biology field [14]. - Wuhan Yijiaobao specializes in the research, production, and sales of high-end orthopedic and biomedical materials, holding multiple medical device registration certificates [14][16]. Group 3: Financial Performance - Dongxing Medical's main business has shown a declining trend since its listing on the Shenzhen Stock Exchange on November 30, 2022 [18]. - From 2021 to 2024, the company's net profit after deducting non-recurring gains and losses has decreased from 1.03 billion to approximately 66.46 million [19]. - In the first half of 2025, Dongxing Medical reported a 14.17% year-on-year decline in revenue to 183.29 million, and a 36.47% drop in net profit to 30.29 million [22].

Core Viewpoint - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao, which is expected to constitute a major asset restructuring [2][10] Group 1: Acquisition Details - On September 26, Dongxing Medical signed a "Share Acquisition Intent Agreement" with all shareholders of Wuhan Yijiaobao to purchase 90% of its equity for cash [3][4] - The final transaction price will be based on an evaluation report from a qualified asset appraisal agency as per the Securities Law of the People's Republic of China [9] - A exclusivity period is set from the signing date until May 31, 2026, during which the current shareholders cannot negotiate with other parties regarding the equity transfer [9] Group 2: Strategic Rationale - The acquisition aligns with Dongxing Medical's business development strategy and aims to integrate high-quality industry resources, extending its surgical medical device supply chain and actively expanding into the synthetic biology field [11][13] - Wuhan Yijiaobao specializes in high-end orthopedic and biomedical materials, holding multiple medical device registration certificates [11][13] Group 3: Financial Performance - Dongxing Medical's main business has shown a declining trend since its listing on November 30, 2022, with net profits decreasing from 1.03 billion yuan in 2021 to an estimated 664.59 million yuan in 2024 [15] - In the first half of 2025, Dongxing Medical's revenue fell by 14.17% year-on-year to 183.29 million yuan, and net profit dropped by 36.47% to 30.29 million yuan [18][19]

中科通达原计划通过发行股份及支付现金的方式购买深圳星和动力科技有限公司持有的星和动力（北海）科技有限公司100%股权，并同时募集配套资金。 然而，由于公司与交易对方未能就交易方案的部分核心条款达成一致，中科通达于2025年9月19日审议通过了终止本次重大资产重组事项的相关议案，并与 交易对方签署了终止协议。 根据相关规定，中科通达对终止本次重大资产重组事项相关内幕信息知情人买卖公司股票的情况进行了自查。自查期间为《武汉中科通达高新技术股份有限 公司发行股份及支付现金购买资产并募集配套资金暨关联交易预案》披露日至披露终止本次交易事项之日，即2025年3月22日至2025年9月20日。自查范围包 括公司及其董事、监事、高级管理人员，公司控股股东、实际控制人及其董事、监事、高级管理人员，交易对方及有关知情人员，交易标的及其控股股东、 实际控制人、董事、监事、高级管理人员，为本次重大资产重组事项提供服务的中介机构经办人，其他知悉本次交易内幕信息的法人和自然人，以及前述自 然人的配偶、成年子女和父母。 9月25日，武汉中科通达高新技术股份有限公司（以下简称"中科通达"）发布公告，就公司终止重大资产重组事项相关内幕信息知 ...